Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18821044 | METHODS FOR ENRICHING A TARGET POLYNUCLEOTIDE IN A SAMPLE | August 2024 | March 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18803351 | IDENTIFICATION AND USE OF CIRCULATING NUCLEIC ACID TUMOR MARKERS | August 2024 | April 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18802544 | MOLECULAR MARKER SIGNIFICANTLY ASSOCIATED WITH VITAMIN E CONTENT IN SOYBEANS, KOMPETITIVE ALLELE SPECIFIC POLYMERASE CHAIN REACTION PRIMERS COMBINATION AND APPLICATION THEREOF | August 2024 | December 2024 | Allow | 5 | 0 | 0 | Yes | No |
| 18739680 | KIT, DEVICE, AND METHOD FOR DETECTING LUNG CANCER | June 2024 | June 2025 | Allow | 13 | 1 | 1 | No | No |
| 18665479 | ENRICHMENT OF CIRCULATING TUMOR DNA | May 2024 | May 2025 | Allow | 12 | 3 | 0 | Yes | No |
| 18662886 | METHOD FOR EVALUATING TEA PLANT (+)-CATECHIN CONTENT | May 2024 | January 2025 | Allow | 8 | 1 | 0 | No | No |
| 18646971 | Kit for Assaying AFP mRNA for Liver Cancer Diagnosis | April 2024 | January 2025 | Abandon | 8 | 1 | 0 | No | No |
| 18640645 | METHODS OF DETECTING SPATIAL HETEROGENEITY OF A BIOLOGICAL SAMPLE | April 2024 | June 2025 | Allow | 14 | 1 | 1 | No | No |
| 18633462 | METHODS OF PREPARING A DNA FRACTION ENRICHED WITH CIRCULATING TUMOR DNA | April 2024 | October 2024 | Allow | 6 | 2 | 0 | Yes | No |
| 18622489 | MOLECULAR GENETIC APPROACH TO TREATMENT AND DIAGNOSIS OF ALCOHOL AND DRUG DEPENDENCE | March 2024 | January 2025 | Allow | 10 | 1 | 0 | No | No |
| 18614496 | METHOD OF MEASURING CHIMERISM | March 2024 | May 2025 | Abandon | 14 | 0 | 1 | No | No |
| 18444053 | METHODS FOR EARLY PREDICTION, TREATMENT RESPONSE, RECURRENCE AND PROGNOSIS MONITORING OF PANCREATIC CANCER | February 2024 | November 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18430518 | METHYLATION CLASSIFIER FOR DETECTION OF HPV-INDUCED INVASIVE CANCERS, NONHPV-INDUCED GYNAECOLOGICAL AND ANOGENITAL CANCERS AND THEIR HIGH-GRADE PRECURSOR LESIONS | February 2024 | September 2024 | Allow | 8 | 0 | 0 | No | No |
| 18429449 | Application of Feature Gene TRIM22 in Preparation of Reagent Regulating Expression of Breast Cancer-Related Gene | February 2024 | March 2025 | Abandon | 14 | 2 | 0 | No | No |
| 18430156 | METHODS AND COMPOSITIONS FOR DETECTING ESOPHAGEAL NEOPLASIAS AND/OR METAPLASIAS IN THE ESOPHAGUS | February 2024 | October 2024 | Allow | 8 | 1 | 0 | Yes | No |
| 18422247 | ASSAYS FOR FUNGAL INFECTION | January 2024 | July 2025 | Allow | 17 | 1 | 1 | Yes | No |
| 18421579 | ASSAYS FOR FUNGAL INFECTION | January 2024 | April 2025 | Allow | 14 | 1 | 0 | No | No |
| 18419411 | METHODS FOR CHARACTERIZING CELL-FREE NUCLEIC ACID FRAGMENTS | January 2024 | October 2024 | Allow | 8 | 2 | 0 | Yes | No |
| 18418913 | EPIGENETIC MARKERS AND RELATED METHODS AND MEANS FOR THE DETECTION AND MANAGEMENT OF CERTAIN CANCERS | January 2024 | June 2025 | Allow | 17 | 2 | 1 | Yes | No |
| 18412111 | PROBE-BASED ANALYSIS OF NUCLEIC ACIDS AND PROTEINS | January 2024 | January 2025 | Abandon | 12 | 1 | 0 | No | No |
| 18410474 | METHOD FOR TRANSPOSASE-MEDIATED SPATIAL TAGGING AND ANALYZING GENOMIC DNA IN A BIOLOGICAL SAMPLE | January 2024 | May 2025 | Abandon | 16 | 2 | 0 | No | No |
| 18408056 | KIT, DEVICE AND METHOD FOR DETECTING PROSTATE CANCER | January 2024 | January 2025 | Allow | 12 | 1 | 1 | No | No |
| 18394729 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | December 2023 | December 2024 | Allow | 11 | 1 | 0 | No | No |
| 18391117 | MULTIPLEXED FUEL ANALYSIS | December 2023 | June 2025 | Allow | 18 | 0 | 0 | No | No |
| 18530860 | METHODS OF DETECTING A LEAK FROM A SUBARRAY OF A MICROARRAY CHIP, KITS OF COMPONENTS THAT FACILITATE LEAK DETECTION, AND MICROARRAY CHIPS CONFIGURED FOR LEAK DETECTION | December 2023 | September 2024 | Allow | 9 | 2 | 1 | Yes | No |
| 18521390 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR MAST CELL-MEDIATED INFLAMMATORY DISEASES | November 2023 | March 2025 | Abandon | 15 | 0 | 1 | No | No |
| 18517748 | Extracellular mRNA Markers of Muscular Dystrophies in Human Urine | November 2023 | May 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18518079 | METHOD FOR PARENT-OF-ORIGIN DISEASE ALLELE DETECTION FOR THE DIAGNOSIS AND MANAGEMENT OF GENETIC DISEASES | November 2023 | November 2024 | Allow | 12 | 2 | 1 | Yes | No |
| 18517524 | DNA LOCATION METHOD AND APPARATUS | November 2023 | April 2025 | Abandon | 17 | 3 | 0 | No | Yes |
| 18518055 | CONSENSUS CODING SEQUENCES OF HUMAN BREAST AND COLORECTAL CANCER | November 2023 | April 2025 | Abandon | 16 | 0 | 1 | No | No |
| 18513107 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER | November 2023 | December 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18504402 | COMBINATIONS, DETECTION METHODS AND KITS OF DNA METHYLATION BIOMARKER | November 2023 | July 2025 | Allow | 20 | 1 | 1 | Yes | No |
| 18500680 | PREPARATION OF TEMPLATES FOR METHYLATION ANALYSIS | November 2023 | April 2025 | Allow | 17 | 1 | 1 | Yes | No |
| 18379355 | EXTRACT FROM A BODY FLUID COMPRISING A MICRO RNA | October 2023 | June 2025 | Allow | 20 | 3 | 1 | No | No |
| 18464360 | C-RAF Mutants that Confer Resistance to RAF Inhibitors | September 2023 | August 2024 | Allow | 11 | 2 | 1 | Yes | No |
| 18459068 | Compositions and Methods for Analyte Detection | August 2023 | March 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18457770 | METHODS FOR EARLY DETECTION OF CANCER | August 2023 | June 2025 | Abandon | 21 | 1 | 0 | No | No |
| 18454312 | Method to Use Gene Expression to Determine Likelihood of Clinical Outcome of Renal Cancer | August 2023 | May 2025 | Allow | 21 | 1 | 1 | No | No |
| 18452778 | CIRCULATING SERUM MICRORNA BIOMARKERS AND METHODS FOR PARKINSON'S DISEASE PROGNOSIS | August 2023 | May 2025 | Allow | 21 | 1 | 0 | No | No |
| 18450103 | CIRCULATING SERUM CELL-FREE DNA BIOMARKERS AND METHODS | August 2023 | July 2024 | Allow | 11 | 0 | 1 | No | No |
| 18230601 | METHODS FOR TREATING NEUROBLASTOMA | August 2023 | May 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18350566 | HIGHLY STABLE AND SPECIFIC MOLECULAR BEACONS ENCAPSULATED IN CATIONIC LIPOPLEX NANOPARTICLES AND APPLICATION THEREOF | July 2023 | December 2024 | Abandon | 17 | 0 | 1 | No | No |
| 18349807 | KIT FOR DIAGNOSING GASTRIC CANCER USING miRNA EXPRESSION | July 2023 | January 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18339400 | KIT, DEVICE, AND METHOD FOR DETECTING BLADDER CANCER | June 2023 | October 2024 | Allow | 16 | 1 | 1 | Yes | No |
| 18332781 | ANALYTICAL METHODS FOR CELL FREE NUCLEIC ACIDS AND APPLICATIONS | June 2023 | January 2025 | Abandon | 20 | 0 | 1 | No | No |
| 18330112 | METHODS AND COMPOSITIONS FOR PREDICTION OF THERAPEUTIC EFFICACY OF CANCER TREATMENTS AND CANCER PROGNOSIS | June 2023 | August 2024 | Allow | 15 | 1 | 1 | No | No |
| 18328070 | STRATIFICATION AND PROGNOSIS OF CANCER | June 2023 | November 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18327614 | DETECTING OVARIAN CANCER | June 2023 | June 2025 | Allow | 25 | 2 | 1 | No | No |
| 18325500 | Inhibition Of HSD17B13 In The Treatment Of Liver Disease In Patients Expressing The PNPLA3 I148M Variation | May 2023 | December 2024 | Allow | 19 | 2 | 0 | Yes | No |
| 18311703 | DETECTION AND CLASSIFICATION OF IMP CARBAPENEMASES USING REAL-TIME POLYMERASE CHAIN REACTION ASSAY | May 2023 | July 2024 | Allow | 14 | 1 | 0 | No | No |
| 18311644 | COMPOSITIONS AND METHODS FOR BINDING AN ANALYTE TO A CAPTURE PROBE | May 2023 | October 2024 | Abandon | 17 | 2 | 0 | No | No |
| 18141862 | EML4-ALK TRANSLOCATIONS IN LUNG CANCER | May 2023 | January 2025 | Allow | 21 | 2 | 1 | Yes | No |
| 18308706 | Methods and Compositions for Sequentially Detecting Targets | April 2023 | November 2024 | Allow | 19 | 1 | 0 | No | No |
| 18309128 | MANIPULATING AND DETECTING BIOLOGICAL SAMPLES | April 2023 | September 2024 | Allow | 17 | 2 | 1 | Yes | No |
| 18309116 | MANIPULATING AND DETECTING BIOLOGICAL SAMPLES | April 2023 | May 2025 | Abandon | 24 | 4 | 0 | No | Yes |
| 18306648 | METHODS AND COMPOSITIONS FOR RISK PREDICTION, DIAGNOSIS, PROGNOSIS, AND TREATMENT OF PULMONARY DISORDERS | April 2023 | April 2025 | Allow | 24 | 3 | 1 | Yes | No |
| 18302737 | BREAST CANCER SPLICE VARIANTS | April 2023 | April 2025 | Abandon | 24 | 2 | 1 | No | No |
| 18298777 | Methods for Quantification of Nucleosome Modifications and Mutations at Genomic Loci and Clinical Applications Thereof | April 2023 | February 2025 | Abandon | 23 | 1 | 1 | No | No |
| 18131678 | KIT FOR IDENTIFYING MALIGNANCY, AND USES THEREOF | April 2023 | September 2024 | Allow | 17 | 0 | 0 | No | No |
| 18131204 | PKD MUTATIONS AND EVALUATION OF SAME | April 2023 | March 2025 | Abandon | 24 | 3 | 1 | No | No |
| 18191506 | METHODS FOR THE DETECTION AND TREATMENT OF LUNG CANCER | March 2023 | April 2025 | Allow | 24 | 4 | 0 | No | No |
| 18182868 | CIRCULATING SERUM MICRORNA BIOMARKERS AND METHODS FOR ALZHEIMER'S DISEASE DIAGNOSIS | March 2023 | May 2025 | Allow | 26 | 1 | 1 | No | No |
| 18025639 | USE OF microRNA (miRNA) MARKER IN PREPARATION OF PRODUCT FOR EVALUATING THERAPEUTIC EFFECT OF OLANZAPINE IN TREATMENT OF SCHIZOPHRENIA (SZ) AND KIT | March 2023 | July 2024 | Allow | 16 | 1 | 0 | Yes | No |
| 18179825 | ASSOCIATION OF RARE RECURRENT GENETIC VARIATIONS TO ATTENTION-DEFICIT, HYPERACTIVITY DISORDER (ADHD) AND METHODS OF USE THEREOF FOR THE DIAGNOSIS AND TREATMENT OF THE SAME | March 2023 | November 2024 | Abandon | 21 | 1 | 1 | No | No |
| 18112696 | NEEDLE-BASED DEVICES AND METHODS FOR IN VIVO DIAGNOSTICS OF DISEASE CONDITIONS | February 2023 | January 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18165089 | DEVICES AND METHODS FOR MOLECULE DETECTION BASED ON THERMAL STABILITIES OF MAGNETIC NANOPARTICLES | February 2023 | August 2024 | Allow | 18 | 1 | 1 | No | No |
| 18164175 | MOLECULAR GENETIC APPROACH TO TREATMENT AND DIAGNOSIS OF ALCOHOL AND DRUG DEPENDENCE | February 2023 | December 2024 | Allow | 22 | 1 | 0 | No | No |
| 18163128 | METHODS AND SYSTEMS FOR HIGH-DEPTH SEQUENCING OF METHYLATED NUCLEIC ACID | February 2023 | June 2025 | Allow | 29 | 5 | 1 | Yes | No |
| 18159218 | DETECTING BABESIA SPECIES NUCLEIC ACID IN A SAMPLE | January 2023 | April 2025 | Allow | 27 | 2 | 0 | No | No |
| 18152127 | METHODS OF DETECTING AND TYPING PATHOGENIC STRAINS OF FRANCISELLA TULARENSIS | January 2023 | February 2025 | Allow | 25 | 1 | 1 | No | No |
| 18003658 | EPIGENETIC BIOMARKER COMPOSITION FOR DIAGNOSING DOWN SYNDROME, AND USE THEREOF | December 2022 | June 2025 | Allow | 30 | 3 | 1 | Yes | No |
| 18147134 | Method of Determining Acute Myeloid Leukemia Response to Treatment With Farnesyltransferase Inhibitors | December 2022 | December 2024 | Allow | 23 | 1 | 0 | No | No |
| 18069550 | DETECTING COLORECTAL NEOPLASIA | December 2022 | April 2025 | Allow | 28 | 1 | 1 | No | No |
| 18083221 | METHODS FOR PROSTATE CANCER DETECTION | December 2022 | January 2025 | Allow | 26 | 2 | 1 | Yes | No |
| 18067661 | MULTIMODAL ANALYSIS OF CIRCULATING TUMOR NUCLEIC ACID MOLECULES | December 2022 | June 2025 | Abandon | 30 | 2 | 1 | Yes | No |
| 18066693 | METHOD OF PREDICTING RISK OF RECURRENCE OF CANCER | December 2022 | April 2025 | Abandon | 28 | 0 | 1 | No | No |
| 18063015 | METHODS OF TREATING TUMOR | December 2022 | December 2024 | Abandon | 25 | 2 | 1 | No | No |
| 17994894 | Biomarkers for the Diagnosis of Parkinson's Disease | November 2022 | June 2025 | Abandon | 30 | 3 | 1 | Yes | No |
| 17991739 | METHODS AND SYSTEMS FOR DETECTING TISSUE CONDITIONS | November 2022 | December 2024 | Abandon | 24 | 1 | 1 | No | No |
| 17991429 | SYSTEMS AND METHODS FOR NUCLEIC ACID SEQUENCING | November 2022 | February 2025 | Abandon | 27 | 1 | 1 | No | No |
| 17987424 | METHODS AND COMPOSITIONS FOR INHIBITING AND TREATING NEUROLOGICAL CONDITIONS | November 2022 | May 2025 | Abandon | 30 | 1 | 0 | No | No |
| 18050855 | METHODS AND SYSTEMS FOR IMPROVING PATIENT MONITORING AFTER SURGERY | October 2022 | January 2024 | Abandon | 15 | 2 | 1 | Yes | No |
| 17973055 | DETECTION UNITS AND METHODS FOR DETECTING A TARGET ANALYTE | October 2022 | January 2025 | Allow | 26 | 1 | 1 | Yes | No |
| 17967277 | GENE AND MUTATIONS THEREOF ASSOCIATED WITH SEIZURE AND MOVEMENT DISORDERS | October 2022 | February 2025 | Allow | 28 | 4 | 1 | No | No |
| 17962752 | Method and Device for Encapsulating Cell in Liquid Droplet for Single-Cell Analysis | October 2022 | December 2024 | Allow | 26 | 1 | 0 | Yes | No |
| 17960026 | CUSTOMIZED ASSAYS FOR PERSONALIZED CANCER MONITORING | October 2022 | January 2025 | Allow | 27 | 3 | 1 | Yes | No |
| 17957999 | MULTIOMIC ANALYSIS DEVICE AND METHODS OF USE THEREOF | September 2022 | November 2024 | Abandon | 25 | 4 | 1 | Yes | Yes |
| 17956050 | Methods for Identifying Progression of a Primary Melanoma | September 2022 | February 2025 | Allow | 28 | 2 | 0 | Yes | No |
| 17955426 | POLYMORPHISM DETECTION WITH INCREASED ACCURACY | September 2022 | December 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17820925 | Clear Cell Renal Cell Carcinoma Biomarkers | August 2022 | August 2024 | Allow | 24 | 1 | 0 | Yes | No |
| 17883223 | DIAGNOSTIC TEST FOR PREDICTING METASTASIS AND RECURRENCE IN CUTANEOUS MELANOMA | August 2022 | March 2025 | Allow | 31 | 2 | 0 | No | No |
| 17817452 | BIOMARKERS FOR HEAD AND NECK CANCER AND METHODS OF THEIR USE | August 2022 | January 2025 | Allow | 30 | 2 | 1 | Yes | No |
| 17877830 | MARKERS TO PREDICT MACROCYCLIC LACTONE DRUG RESISTANCE IN DIROFILARIA IMMITIS, THE CAUSATIVE AGENT OF HEARTWORM DISEASE | July 2022 | April 2025 | Allow | 33 | 1 | 1 | No | No |
| 17815008 | METHODS FOR COLON CANCER DETECTION AND TREATMENT | July 2022 | January 2025 | Allow | 30 | 1 | 0 | No | No |
| 17815102 | METHODS FOR PROSTATE CANCER DETECTION AND TREATMENT | July 2022 | May 2025 | Abandon | 33 | 1 | 0 | No | No |
| 17813965 | ASSAY METHODS | July 2022 | May 2025 | Allow | 34 | 2 | 1 | No | No |
| 17812415 | OPTIMIZATION OF MULTIGENE ANALYSIS OF TUMOR SAMPLES | July 2022 | August 2024 | Allow | 25 | 1 | 1 | No | No |
| 17861218 | DNA LOCATION METHOD AND APPARATUS | July 2022 | May 2025 | Allow | 34 | 4 | 0 | Yes | Yes |
| 17811192 | CALIBRATION PANELS AND METHODS FOR DESIGNING THE SAME | July 2022 | March 2025 | Abandon | 32 | 2 | 0 | Yes | No |
| 17810816 | Methods Of Treating Skin Cancer With Histidine Ammonia-Lyase (HAL) Agonists | July 2022 | August 2024 | Allow | 26 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1682.
With a 75.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 36.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Art Unit 1682 is part of Group 1680 in Technology Center 1600. This art unit has examined 1,200 patent applications in our dataset, with an overall allowance rate of 84.5%. Applications typically reach final disposition in approximately 40 months.
Art Unit 1682's allowance rate of 84.5% places it in the 77% percentile among all USPTO art units. This art unit has a significantly higher allowance rate than most art units at the USPTO.
Applications in Art Unit 1682 receive an average of 2.36 office actions before reaching final disposition (in the 86% percentile). The median prosecution time is 40 months (in the 6% percentile).
When prosecuting applications in this art unit, consider the following:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.